Option chain shows key data for BiomX's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for BiomX.

BiomX (AMEX:PHGE) Stock, Option Chain

BIOMX INC

BiomX

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Display,Of,Stock,Market,Quotes

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACXP

BMEA

CBIO

CERO

EYEN

GOVX

GURE

HSDT

LDTC

LIMN

PHGE

PTLE

SAFX

VNCE

XAIR

Why Beyond Air Shares Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket

Side,View,Of,Concentrated,Crypto,Trader,Sitting,In,Front,Of

Price Target

Analyst Ratings

BCAX

CRWV

DAVA

RCKT

Pentair To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Friday

UltaBeautyGreenwood,,Indiana, - ,United,States,-,June,16,2020:,Beauty

FWRG

PCVX

RVPH

TVTX

ULTA

Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday

BiomX Inc

BiomX Inc Warrants (13/12/2023)

Press Releases

BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards

Financing

BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million

BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Earnings

BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates

BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

General

BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference

BiomX Stock Could Soar 3000% As This $10M Biotech Cracks The 'Superbug' Code, Wall Street Says

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Ainos

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Aprea Therapeutics

BioCardia

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Equillium

Genprex

GT Biopharma

HCW Biologics

Immuron Limited - American Depositary Shares

Immuron

Kairos Pharma

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals

Moleculin Biotech

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

NextCure

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Turnstone Biologics

XTL Biopharmaceuticals Ltd. - American Depositary Shares

XTL Biopharmaceuticals

HC Wainwright & Co.

Laidlaw & Co.

Chardan Capital

Comments

BiomX

BiomX (PHGE) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell